EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Economic Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis and Low Surgical Risk: Results from the PARTNER 3 Trial

Benjamin Z Galper, Khaja M Chinnakondepalli, Kaijun Wang, Elizabeth A Magnuson iD, Michael Lu iD, Vinod H Thourani, Susheel Kodali, Raj Makkar, Howard C Herrmann iD, Samir Kapadia iD, Mathew Williams, John Webb und 5 weitere

Circulation · 23.05.2023 · 147 (21) · 1594-1605

DOI: 10.1161/circulationaha.122.062481 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Circulation, erschienen am 23.05.2023. Verfasst von Benjamin Z Galper und 16 weiteren Autor:innen. Beteiligte Einrichtung: Mid-Atlantic Permanente Medical Group, McLean, VA (B.Z.G.). Hauptthemen laut MEDLINE: Heart Valve Prosthesis Implantation, Transcatheter Aortic Valve Replacement, Aortic Valve Stenosis. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Edwards Lifesciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In patients with severe symptomatic aortic stenosis at low surgical risk, transfemoral transcatheter aortic valve replacement (TAVR) with the SAPIEN 3 valve has been shown to reduce the composite of death, stroke, or rehospitalization at 2-year follow-up compared with surgical aortic valve replacement (SAVR). Whether TAVR is cost-effective compared with SAVR for low-risk patients remains uncertain.

Methods

Between 2016 and 2017, 1000 low-risk patients with aortic stenosis were randomly assigned to TAVR with the SAPIEN 3 valve or SAVR in the PARTNER 3 trial (Placement of Aortic Transcatheter Valves). Of these patients, 929 underwent valve replacement, were enrolled in the United States, and were included in the economic substudy. Procedural costs were estimated using measured resource use. Other costs were determined by linkage with Medicare claims or by regression models when linkage was not feasible. Health utilities were estimated using the EuroQOL 5-item questionnaire. With the use of a Markov model informed by in-trial data, lifetime cost-effectiveness from the perspective of the US health care system was estimated in terms of cost per quality-adjusted life-year gained.

Results

Although procedural costs were nearly $19 000 higher with TAVR, total index hospitalization costs were only $591 more with TAVR compared with SAVR. Follow-up costs were lower with TAVR such that TAVR led to 2-year cost savings of $2030/patient compared with SAVR (95% CI, –$6222 to $1816) and a gain of 0.05 quality-adjusted life-years (95% CI, –0.003 to 0.102). In our base-case analysis, TAVR was projected to be an economically dominant strategy with a 95% probability that the incremental cost-effectiveness ratio for TAVR would be

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart Valve Prosthesis ImplantationTranscatheter Aortic Valve ReplacementAortic Valve StenosisHumansAgedUnited StatesAortic ValveTreatment OutcomeMedicareRisk Factors

Stichwörter der Autor:innen

aortic valve stenosiscost-benefit analysiscost-effectiveness analysisquality of lifetranscatheter aortic valve replacement

Autor:innen und Institutionen

  • Mid-Atlantic Permanente Medical Group, McLean, VA (B.Z.G.).
  • Saint-Luke's Mid America Heart Institute, Kansas City, MO (K.M.C., K.W., E.A.M.).
  • Edwards Lifesciences, Irvine, CA (M.L.).
  • Piedmont Heart Institute, Atlanta, GA (V.H.T.).
  • New York-Presbyterian/Columbia University Irving Medical Center, New York (S. Kodali, C.R.S., M.B.L.).
  • Cedars-Sinai Medical Center, Los Angeles, CA (R.M.).

ORCID-Profile: Elizabeth A Magnuson, Michael Lu, Howard C Herrmann, Samir Kapadia, Michael J Mack, David J Cohen

Förderung

  • Edwards Lifesciences

Zitieren

APA

Galper, B. Z., Chinnakondepalli, K. M., Wang, K., Magnuson, E. A., Lu, M., Thourani, V. H., Kodali, S., Makkar, R., Herrmann, H. C., Kapadia, S., Williams, M., Webb, J., Smith, C. R., Mack, M. J., Leon, M. B., Cohen, D. J., & PARTNER Investigators (2023). Economic Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis and Low Surgical Risk: Results from the PARTNER 3 Trial. Circulation, 147(21), 1594-1605. https://doi.org/10.1161/circulationaha.122.062481

Vancouver

Galper BZ, Chinnakondepalli KM, Wang K, Magnuson EA, Lu M, Thourani VH, et al. Economic Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis and Low Surgical Risk: Results from the PARTNER 3 Trial. Circulation. 2023;147(21):1594-1605. doi:10.1161/circulationaha.122.062481

BibTeX
@article{Galper2023,
  author = {Galper, Benjamin Z and Chinnakondepalli, Khaja M and Wang, Kaijun and Magnuson, Elizabeth A and Lu, Michael and Thourani, Vinod H and Kodali, Susheel and Makkar, Raj and Herrmann, Howard C and Kapadia, Samir and Williams, Mathew and Webb, John and Smith, Craig R and Mack, Michael J and Leon, Martin B and Cohen, David J and PARTNER Investigators, PARTNER Investigators},
  title = {Economic Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis and Low Surgical Risk: Results from the PARTNER 3 Trial},
  journal = {Circulation},
  year = {2023},
  volume = {147},
  number = {21},
  pages = {1594--1605},
  doi = {10.1161/circulationaha.122.062481}
}
Kostenlos starten →